These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30222644)

  • 1. Individual and Geospatial Characteristics Associated With Use and Nonuse of the Fecal Immunochemical Test (FIT) for Colorectal Cancer Screening in an Urban Minority Population.
    Ramai D; Etienne D; Ayide G; Fields PJ; Reddy M
    J Clin Gastroenterol; 2019; 53(10):744-749. PubMed ID: 30222644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal Immunochemical Test Screening and Risk of Colorectal Cancer Death.
    Doubeni CA; Corley DA; Jensen CD; Levin TR; Ghai NR; Cannavale K; Zhao WK; Selby K; Buckner-Petty S; Zauber AG; Fletcher RH; Weiss NS; Schottinger JE
    JAMA Netw Open; 2024 Jul; 7(7):e2423671. PubMed ID: 39028667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A community-based trial of educational interventions with fecal immunochemical tests for colorectal cancer screening uptake among blacks in community settings.
    Christy SM; Davis SN; Williams KR; Zhao X; Govindaraju SK; Quinn GP; Vadaparampil ST; Lin HY; Sutton SK; Roethzeim RR; Shibata D; Meade CD; Gwede CK
    Cancer; 2016 Nov; 122(21):3288-3296. PubMed ID: 27420119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moderators of the effectiveness of an intervention to increase colorectal cancer screening through mailed fecal immunochemical test kits: results from a pragmatic randomized trial.
    O'Connor EA; Vollmer WM; Petrik AF; Green BB; Coronado GD
    Trials; 2020 Jan; 21(1):91. PubMed ID: 31941527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Primary Care Visits and Colorectal Cancer Screening Outcomes in the Era of Population Health Outreach.
    Halm EA; Beaber EF; McLerran D; Chubak J; Corley DA; Rutter CM; Doubeni CA; Haas JS; Balasubramanian BA
    J Gen Intern Med; 2016 Oct; 31(10):1190-7. PubMed ID: 27279097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician-office vs home uptake of colorectal cancer screening using FOBT/FIT among screening-eligible US adults.
    Chido-Amajuoyi OG; Sharma A; Talluri R; Tami-Maury I; Shete S
    Cancer Med; 2019 Dec; 8(17):7408-7418. PubMed ID: 31637870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with use and non-use of the Fecal Immunochemical Test (FIT) kit for Colorectal Cancer Screening in Response to a 2012 outreach screening program: a survey study.
    Gordon NP; Green BB
    BMC Public Health; 2015 Jun; 15():546. PubMed ID: 26062732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake of colorectal cancer screening after mailed fecal immunochemical test (FIT) outreach in a newly eligible 45-49-year-old community health center population.
    O'Leary MC; Reuland DS; Correa SY; Moore AA; Malo TL; Tan X; Rohweder CL; Wheeler SB; Brenner AT
    Cancer Causes Control; 2023 Dec; 34(Suppl 1):125-133. PubMed ID: 37300632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What are the contextual risk factors for low colorectal cancer screening uptake in El Paso County, Texas? Spatial cross-sectional analysis.
    Salinas J; Brito J; Rincones C; Shokar NK
    BMJ Open; 2020 Oct; 10(10):e038342. PubMed ID: 33040009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Screening of African Americans (45-50 Years Old) in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program.
    Levin TR; Jensen CD; Chawla NM; Sakoda LC; Lee JK; Zhao WK; Landau MA; Herm A; Eby E; Quesenberry CP; Corley DA
    Gastroenterology; 2020 Nov; 159(5):1695-1704.e1. PubMed ID: 32702368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System.
    Mehta SJ; Jensen CD; Quinn VP; Schottinger JE; Zauber AG; Meester R; Laiyemo AO; Fedewa S; Goodman M; Fletcher RH; Levin TR; Corley DA; Doubeni CA
    J Gen Intern Med; 2016 Nov; 31(11):1323-1330. PubMed ID: 27412426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics.
    Davis SN; Christy SM; Chavarria EA; Abdulla R; Sutton SK; Schmidt AR; Vadaparampil ST; Quinn GP; Simmons VN; Ufondu CB; Ravindra C; Schultz I; Roetzheim RG; Shibata D; Meade CD; Gwede CK
    Cancer; 2017 Apr; 123(8):1390-1400. PubMed ID: 27906448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Against colorectal cancer in our neighborhoods (ACCION): A comprehensive community-wide colorectal cancer screening intervention for the uninsured in a predominantly Hispanic community.
    Shokar NK; Byrd T; Salaiz R; Flores S; Chaparro M; Calderon-Mora J; Reininger B; Dwivedi A
    Prev Med; 2016 Oct; 91():273-280. PubMed ID: 27575314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Finding the Right FIT": Rural Patient Preferences for Fecal Immunochemical Test (FIT) Characteristics.
    Pham R; Cross S; Fernandez B; Corson K; Dillon K; Yackley C; Davis MM
    J Am Board Fam Med; 2017; 30(5):632-644. PubMed ID: 28923816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention-sponsored Summit.
    Gupta S; Coronado GD; Argenbright K; Brenner AT; Castañeda SF; Dominitz JA; Green B; Issaka RB; Levin TR; Reuland DS; Richardson LC; Robertson DJ; Singal AG; Pignone M
    CA Cancer J Clin; 2020 Jul; 70(4):283-298. PubMed ID: 32583884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of Colon Cancer Screening by Fecal Immunochemical Test in Iran.
    Salimzadeh H; Bishehsari F; Sauvaget C; Amani M; Hamzehloo G; Nikfarjam A; Merat S; Delavari A; Malekzadeh R
    Arch Iran Med; 2017 Dec; 20(12):726-733. PubMed ID: 29664311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rates on the acceptance of colonoscopy, fecal immunochemical test and a novel risk-adapted screening approach in the screening programs of colorectal cancer as well as related associated factors].
    Chen HD; Lu M; Liu CC; Zhang YH; Zou SM; Shi JF; Ren JS; Li N; Dai M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Oct; 41(10):1655-1661. PubMed ID: 33297622
    [No Abstract]   [Full Text] [Related]  

  • 19. Patient Test Preference for Colorectal Cancer Screening and Screening Uptake in an Insured Urban Minority Population.
    Wolf RL; Basch CE; Zybert P; Basch CH; Ullman R; Shmukler C; King F; Neugut AI
    J Community Health; 2016 Jun; 41(3):502-8. PubMed ID: 26585609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
    Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
    Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.